bvFTD is a clinical phenotype, and, currently there is no in vivo marker that can disentangle the underlying pathology, namely tauopathy or TAR DNA-binding protein 43 (TDP-43) proteinopathy. This evidence concerns the gene TARDBP and behavioral variant of frontotemporal dementia.